Browsing Tag
Eli Lilly
51 posts
Novo Nordisk’s Amycretin outshines rivals in weight-loss drug trials
Novo Nordisk has achieved a critical milestone in the fight against obesity, reporting highly promising results from an…
Schrödinger stock skyrockets as Novartis invests billions in new partnership
In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement…
Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?
Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a…
AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The…
UK approves Lilly’s Alzheimer’s drug but labels it ‘too expensive’ for NHS use
The UK has approved Eli Lilly’s new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline.…
New hope for eczema sufferers as FDA approves Eli Lilly’s EBGLYSS
Eli Lilly and Company (Lilly) has secured approval from the U.S. Food and Drug Administration (FDA) for its…
Eli Lilly to expand manufacturing with $1bn investment in Ireland to boost Alzheimer’s drug production
Eli Lilly and Company (NYSE: LLY) has announced a substantial $1 billion investment to expand its Limerick, Ireland,…
Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal,…
Eli Lilly to acquire Morphic in $3.2bn deal to expand integrin therapy development
In a major strategic move, Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire…
FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer’s treatment developed by Eli Lilly…